

Massive Bio Publishes the Second Issue of Massive Bio magazine

Massive Bio announces the publication of the second issue of Massive Bio magazine, which debuted in August.

NEW YORK, USA, October 31, 2022 /EINPresswire.com/ -- Massive Bio, a leader in AI-powered cancer clinical trial enrollment, has published the second issue of Massive Bio magazine. The publication, which had a successful debut in August, features a variety of content for cancer patients and their families, clinicians, and the business community. Featured content in the second issue includes updates on Massive Bio, the latest oncology therapies, cancer and lifestyle, and technology in cancer treatment, as well as stories about cancer patients and their caregivers and advocates.

Beyond Chemotherapy

One of the highlights of the second issue of Massive Bio is an interview with Arturo Loaiza-Bonilla, MD, the company's chief medical officer and co-founder, who discusses how new oncology treatment options are allowing many cancer patients to go "beyond chemotherapy," resulting in improved outcomes. The second issue also features news about clinical trials of cutting-edge treatments for myelofibrosis, lymphoma, and melanoma, as well as novel therapies that target cancer biomarkers. In a focus on technology, the role of artificial intelligence (AI) in medicine is examined, including an explanation of how Massive Bio uses AI to identify the right clinical trial for cancer patients.

Taking Care

The cover story of the second issue of Massive Bio, "Taking Care," looks at caregivers of people with cancer and other chronic conditions, and why they need to care for themselves, too.



Massive Bio Publishes the Second Issue of Massive Bio magazine

Another story explores intriguing evidence that diet changes may help prevent and control cancer. Finally, we get to know Brian McCloskey, a patient who is using data to fight prostate cancer, and helping other men do the same; and learn about Pink Fund, an advocacy group that provides financial assistance to breast cancer patients struggling with mounting bills.

Massive Bio magazine is available in English, Italian, Spanish, Polish, and Turkish, and can be read on the company website and various magazine platforms.

About Massive Bio

Massive Bio's mission is to provide access to clinical trials for cancer patients worldwide, regardless of where they live or their financial circumstances. Founded in New York City in 2015, Massive Bio solves bottlenecks in recruiting patients for clinical trials with a unique technology-enabled service and big data platform. The company serves pharmaceutical companies, contract research organizations, and hospital networks with a focus on improving the lives of cancer patients and provides oncology-specific data-driven patient recruitment, site selection, and AI-based trial pre-screening services.

Media contact:

Merve Sahin

msahin@massivebio.com

Merve Sahin

Massive Bio

+90 5335649965

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

[Other](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/598718709>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.